Search results for "Angiogenesi"

showing 10 items of 568 documents

Brain and Cancer: The Protective Role of Erythropoietin

2005

Erythropoietin (Epo) is a pleiotropic agent, that is to say, it can act on several cell types in different ways. An independent system Epo/Epo receptor (EpoR) was detected in brain, leading to the hypothesis that this hormone could be involved in cerebral functions. Epo/EpoR expression changes during ontogenesis, thus indicating the importance of this system in neurodevelopment. Moreover, the hypoxia-induced production of Epo in the adult brain suggests that it could exert a neurotrophic and neuroprotective effect in case of brain injury. Epo could also influence neuro- transmission, inducing neurotransmitters (NT) release. Epo therapy in anemic cancer patients is still a controversial issu…

Cell typeCentral nervous systemPharmacologyModels BiologicalNeuroprotectionNeoplasmshemic and lymphatic diseasesDrug DiscoveryReceptors ErythropoietinmedicineAnimalsHumanscancerReceptorPleiotropyPharmacologyNeurotransmitter AgentsNeovascularization Pathologicbiologyhypoxiabusiness.industryMedicine (all)Organic ChemistryBrainangiogenesiGeneral MedicineNeuroprotectionneuroprotective effectErythropoietin receptorErythropoietin (Epo); brain; central nervous system (CNS) diseases; neuroprotective effectmedicine.anatomical_structureErythropoietin (Epo)Erythropoietinbiology.proteinMolecular MedicineerythropoietinSignal transductionbusinessNeurosciencecentral nervous system (CNS) diseasesmedicine.drugNeurotrophinChemInform
researchProduct

MicroRNAs: Promising New Antiangiogenic Targets in Cancer

2014

[EN] MicroRNAs are one class of small, endogenous, non-coding RNAs that are approximately 22 nucleotides in length; they are very numerous, have been phylogenetically conserved, and involved in biological processes such as development, differentiation, cell proliferation, and apoptosis. MicroRNAs contribute to modulating the expression levels of specific proteins based on sequence complementarity with their target mRNA molecules and so they play a key role in both health and disease. Angiogenesis is the process of new blood vessel formation from preexisting ones, which is particularly relevant to cancer and its progression. Over the last few years, microRNAs have emerged as critical regulat…

Cell typeDOWN-REGULATIONArticle SubjectAngiogenesisHUMAN BREAST-CANCERMIR-200 FAMILYlcsh:MedicineAngiogenesis InhibitorsReview ArticleBiologyBioinformaticsGeneral Biochemistry Genetics and Molecular BiologyNUCLEAR EXPORTTUMOR ANGIOGENESISNeovascularizationMicroprocessor complexSMALL RNASDownregulation and upregulationNeoplasmsmicroRNAGene expressionmedicineAnimalsHumansMolecular Targeted TherapyPrecision MedicineIN-VIVOGENE-EXPRESSIONGeneral Immunology and MicrobiologyNeovascularization PathologicCell growthlcsh:RMICROBIOLOGIAGeneral MedicineMICROPROCESSOR COMPLEXMicroRNAsENDOTHELIAL GROWTH-FACTORCancer researchmedicine.symptom
researchProduct

Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma

2015

Interleukin (IL)-17A belongs to IL-17 superfamily and binds the heterodimeric IL-17 receptor (R)(IL-17RA/IL-17RC). IL-17A promotes germinal center (GC) formation in mouse models of autoimmune or infectious diseases, but the role of IL-17A/IL-17AR complex in human neoplastic GC is unknown. In this study, we investigated expression and function of IL-17A/IL-17AR in the microenvironments of 44 B cell non-Hodgkin lymphomas (B-NHL) of GC origin (15 follicular lymphomas, 17 diffuse large B cells lymphomas and 12 Burkitt lymphomas) and 12 human tonsil GC. Furthermore, we investigated the role of IL-17A in two in vivo models of GC B cell lymphoma, generated by s.c. injection of SU-DHL-4 and OCI-Ly8…

Cell typeImmunologySettore MED/08 - Anatomia PatologicaangiogenesisB non-Hodgkin lymphomahemic and lymphatic diseasesmedicineIL-17AImmunology and Allergytumor immunologyCXCL13B-cell lymphomaangiogenesis; B non-Hodgkin lymphoma; GC B cells; IL-17A; IL-17A receptor; tumor immunology; Immunology and Allergy; Oncology; ImmunologyB cellOriginal ResearchSevere combined immunodeficiencybusiness.industryIL-17A receptorGerminal centerInterleukinangiogenesimedicine.diseaseMolecular biologyGC B cellmedicine.anatomical_structureOncologyCell cultureImmunologyGC B cellsbusiness
researchProduct

Biodistribution, Uptake and Effects Caused by Cancer-derived Extracellular Vesicles

2015

Extracellular vesicles (EVs) have recently emerged as important mediators of intercellular communication. They are released in the extracellular space by a variety of normal and cancerous cell types and have been found in all human body fluids. Cancer-derived EVs have been shown to carry lipids, proteins, mRNAs, non-coding and structural RNAs and even extra-chromosomal DNA, which can be taken up by recipient cells and trigger diverse physiological and pathological responses. An increasing body of evidence suggests that cancer-derived EVs mediate paracrine signalling between cancer cells. This leads to the increased invasiveness, proliferation rate and chemoresistance, as well as the acquisi…

Cell typeStromal cellimmunosuppressionAngiogenesisBiochemistry (medical)Clinical BiochemistryReview ArticleBiologyExtracellular vesiclesmetastatic nichelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282Cell biologyExtracellular vesicles; biodistribution; trafficking; tumour microenvironment; immunosuppression; metastatic nicheParacrine signallingCancer stem celltraffickingCancer cellExtracellulartumour microenvironmentReprogrammingbiodistributiontraffick‐ ingJournal of Circulating Biomarkers
researchProduct

L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer

2012

Recent work identified L-asparaginase (L-ASP) as a putative therapeutic target for ovarian cancer. We suggest that L-ASP, a dysregulator of glycosylation, would interrupt the local microenvironment, affecting the ovarian cancer cell-endothelial cell interaction and thus angiogenesis without cytotoxic effects. Ovarian cancer cell lines and human microvascular endothelial cells (HMVEC) were exposed to L-ASP at physiologically attainable concentrations and subjected to analyses of endothelial tube formation, invasion, adhesion and the assessment of sialylated proteins involved in matrix-associated and heterotypic cell adhesion. Marked reduction in HMVEC tube formation in vitro, HMVEC and ovari…

Cell typeautophagyGlycosylationAngiogenesisCellOligosaccharidesAngiogenesis InhibitorsBiologyL-asparaginase; ovarian cancer; angiogenesisCell-Matrix JunctionsangiogenesisSettore BIO/13 - Biologia ApplicataCell Line TumorE-selectinmedicineCell AdhesionHumansCell adhesionSialyl Lewis X AntigenTube formationOvarian NeoplasmsNeovascularization PathologicIntegrin beta1AutophagyEndothelial CellsCell BiologyOriginal Articlesmedicine.diseaseasparaginaseL-asparaginaseCell biologymedicine.anatomical_structureovarian cancersialyl Lewis Xbiology.proteinMolecular MedicineFemaleOvarian cancerE-Selectin
researchProduct

Tumor biology and experimental therapeutics.

2000

Recent research using multicellular tumor spheroids has resulted in new insights in the regulation of invasion and metastasis, angiogenesis and cell cycle kinetics. The onset and expansion of central necrosis in tumor spheroids has been characterized to be a complex interaction of several mechanisms; in a number of cases, necrosis is not a consequence of hypoxia or anoxia, but emerges as secondary necrosis following an accumulation of apoptosis in spheroids. Recent therapeutically oriented studies have been directed towards novel hypoxic markers, targeted therapy, multicellular-mediated drug resistance, and heavy ion irradiation of spheroids. Research efforts should be enhanced mainly in th…

Cellular pathologyPathologymedicine.medical_specialtyNecrosisRadiotherapyAngiogenesisCell growthmedicine.medical_treatmentSpheroidAntineoplastic AgentsHematologyBiologyTargeted therapyOncologyApoptosisNeoplasmsSpheroids Cellularembryonic structuresCell Cycle KineticsmedicineCancer researchHumansImmunotherapymedicine.symptomCritical reviews in oncology/hematology
researchProduct

The angiopoietin-Tie2 pathway regulates Purkinje cell dendritic morphogenesis in a cell-autonomous manner.

2021

Neuro-vascular communication is essential to synchronize central nervous system development. Here, we identify angiopoietin/Tie2 as a neuro-vascular signaling axis involved in regulating dendritic morphogenesis of Purkinje cells (PCs). We show that in the developing cerebellum Tie2 expression is not restricted to blood vessels, but it is also present in PCs. Its ligands angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2) are expressed in neural cells and endothelial cells (ECs), respectively. PC-specific deletion of Tie2 results in reduced dendritic arborization, which is recapitulated in neural-specific Ang1-knockout and Ang2 full-knockout mice. Mechanistically, RNA sequencing reveals that Tie…

CerebellumalphaCytoskeleton organizationAngiogenesisPurkinje cellprotocadherinsMorphogenesisneural progenitor cellsMice Transgenicself-avoidanceBiologyModels BiologicalGeneral Biochemistry Genetics and Molecular BiologyAngiopoietinAngiopoietin-2Purkinje Cellsddc:570CerebellumexpressionGene expressionmedicineAngiopoietin-1MorphogenesisAnimalsmouseMice KnockoutIntegrasessubventricular zonedifferentiationDendritesmtorc2Angiopoietin receptorReceptor TIE-2Cell biologyMice Inbred C57BLmedicine.anatomical_structuremessenger-rnaGene Expression RegulationOrgan Specificityembryonic structurescardiovascular systembiology.proteinGene DeletionSignal TransductionCell reports
researchProduct

Chemokine Expression Is Involved in the Vascular Neogenesis of Ewing Sarcoma: A Preliminary Analysis of the Early Stages of Angiogenesis in a Xenogra…

2018

Background Ewing sarcoma (EWS) is the second most common bone cancer in pediatric patients. Angiogenesis is a major factor for tumor growth and metastasis. Our aim was to carry out a histological, immunohistochemical, and molecular characterization of the neovascularization established between xenotransplanted tumors and the host during the initial phases of growth in nude mice in three angiogenesis experiments (ES2, ES3, and ES4). Methods The original human EWS were implanted subcutaneously on the backs of three nude mice. Tumor pieces 3 mm–4 mm in size from early passages of Nu432, Nu495, and Nu471 were also implanted subcutaneously on the backs of three sets (ES2, ES3, and ES4) of athymi…

ChemokineAngiogenesisMice NudeBone NeoplasmsSarcoma EwingNeogenesisPathology and Forensic MedicinePreliminary analysisMetastasis03 medical and health sciencesMice0302 clinical medicinemedicineBiomarkers TumorAnimalsHumansTumor growthMice Inbred BALB C030219 obstetrics & reproductive medicinebiologyNeovascularization Pathologicbusiness.industryBone cancerGeneral Medicinemedicine.diseasebiology.organism_classificationImmunohistochemistryMicroscopy Electron030220 oncology & carcinogenesisPediatrics Perinatology and Child HealthCancer researchbiology.proteinSarcomaChemokinesbusinessNeoplasm TransplantationPediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
researchProduct

SAT0023 Artery Tertiary Lymphoid Organs Occur in Giant Cell Arteritis

2016

Background Arteries are immuno-privileged sites. In advanced atherosclerotic lesions, however, adventitial lymphoid infiltrates, sometimes aggregated in lymphoid follicles (the so called artery tertiary lymphoid organs, ATLO), occur together with marked neoangiogenesis and lymphangiogenesis, and with the extensive induction of high endothelial venules. Objectives To investigate if tertiary lymphoid organs (TLO) are present in GCA and their formation is associated with the ectopic expression of constitutive lymphoid tissue-homing chemokines. Methods RT-PCR, immunohistochemical and immunofluorescence analysis were used to determine the presence of ectopic TLO in GCA and the expression of chem…

ChemokinePathologymedicine.medical_specialtyFollicular dendritic cellsImmunologyHigh endothelial venulesBiologyGeneral Biochemistry Genetics and Molecular BiologyLymphangiogenesisLymphatic systemRheumatologybiology.proteinmedicineImmunology and AllergyEctopic expressionCXCL13B-cell activating factorAnnals of the Rheumatic Diseases
researchProduct

Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour

2014

Abstract Background To explore the activity of pazopanib in solitary fibrous tumour (SFT). Patients and methods In a preclinical study, we compared the activity of pazopanib, sorafenib, sunitinib, regorafenib, axitinib and bevacizumab in a dedifferentiated-SFT (DSFT) xenotransplanted into Severe Combined Immunodeficiency (SCID) mice. Antiangiogenics were administered at their reported optimal doses when mean tumour volume (TV) was 80 mm3. Drug activity was assessed as TV inhibition percentage (TVI%). From May 2012, six consecutive patients with advanced SFT received pazopanib, on a national name-based programme. In one case sunitinib was administered after pazopanib failure. Results In the …

Chemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Administration Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Antineoplastic Agents; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Male; Mice SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sulfonamides; Transplantation Heterologous; Vascular Endothelial Growth Factor Receptor-2; Cancer Research; Oncology; Medicine (all)OncologyMaleCancer ResearchIndolesAxitinibPyridinesPyridinemedicine.medical_treatmentSolitary fibrous tumourAdministration OralAngiogenesis InhibitorsMice SCIDPharmacologyPyrroleAntineoplastic Agentchemistry.chemical_compoundMiceSolitary Fibrous TumorChemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Cancer Research; Oncology; Medicine (all)Transplantation HeterologouMonoclonalSunitinibHumanizedSulfonamidesHeterologousSunitinibMedicine (all)ImidazolesSarcomaMiddle AgedSorafenibPlatelet-Derived Growth Factor betaAxitinibBevacizumabOncologySolitary Fibrous TumorsAdministrationAngiogenesis InhibitorHumanmedicine.drugReceptorPhenylurea CompoundSorafenibOralAdultNiacinamidemedicine.medical_specialtyIndazolesBevacizumabMAP Kinase Signaling SystemTransplantation HeterologousAntineoplastic AgentsSulfonamideAntibodies Monoclonal HumanizedSCIDAntibodiesReceptor Platelet-Derived Growth Factor betaPazopanibInternal medicineRegorafenibmedicineAnimalsHumansChemotherapyPyrrolesImidazoleTyrosine kinaseAgedChemotherapyTransplantationAnimalbusiness.industryPhenylurea CompoundsPazopanibmedicine.diseaseChemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Administration Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Male; Mice SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sorafenib; Sulfonamides; Sunitinib; Transplantation Heterologous; Vascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factor Receptor-2IndazolePyrimidinesPyrimidinechemistryIndolebusinessProgressive diseaseNeoplasm Transplantation
researchProduct